Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: The PASSION study

Transfusion

Volumn 54, Issue 6, 2014, Pages 1552-1561

  Martinez Saguer, Inmaculada ^a   Cicardi, Marco ^b   Suffritti, Chiara ^b   Rusicke, Eva ^c   Aygören Pürsün, Emel ^c   Stoll, Hildegard ^d   Rossmanith, Tanja ^c   Feussner, Annette ^e   Kalina, Uwe ^e   Kreuz, Wolfhart ^a  

^a Hemophilia Center Rhine Main GmbH   (Germany)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d Siemens Healthcare Diagnostics Holding GmbH   (Germany)

^e CSL BEHRING GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COMPLEMENT COMPONENT C1S ANTIGEN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; HIGH MOLECULAR WEIGHT KININOGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; APPLICATION SITE HEMATOMA; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE REACTION; APPLICATION SITE SWELLING; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; OPEN STUDY; OROPHARYNX PAIN; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUSITIS; SPINE DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AGED; ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INHIBITOR PROTEIN; CROSS-OVER STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902262860     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12501     Document Type: Article

References (43)

1. Donaldson VH, Evans RR,. A biochemical abnormality in hereditary angioneurotic oedema: absence of serum inhibitor of C1-esterase. Am J Med 1963; 35: 37-44.
2. Bork K, Siedlecki K, Bosch S, etal. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75: 349-354.
3. Frank MM, Gelfand JA, Atkinson JP,. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84: 580-593.
4. Longhurst H, Cicardi M,. Hereditary angio-edema. Lancet 2012; 379: 474-481.
5. Wuillemin WA, Hack CE, Bleeker WK, etal. Inactivation of factor XIa in vivo: studies in chimpanzees and in humans. Thromb Haemost 1996; 76: 549-555.
6. Garcia JG, Siflinger-Birnboim A, Bizios R, etal. Thrombin-induced increase in albumin permeability across the endothelium. J Cell Physiol 1986; 128: 96-104.
7. Garcia JG, Pavalko FM, Patterson CE,. Vascular endothelial cell activation and permeability responses to thrombin. Blood Coagul Fibrinolysis 1995; 6: 609-626.
8. Cugno M, Cicardi M, Bottasso B, etal. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89: 3213-3218.
9. Bork K,. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol 2010; 6: 15.
10. Hack CE,. Pathogenesis of angioedema attacks. In: Hereditary and acquired angioedema: problems and progress. Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. JACI 2004;114:S75-9.
11. Craig TJ, Levy RJ, Wasserman RL, etal. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-808.
12. Craig TJ, Wasserman RL, Levy RJ, etal. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol 2010; 30: 823-829.
13. Wasserman RL, Levy RJ, Bewtra AK, etal. Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. Ann Allergy Asthma Immunol 2011; 106: 62-68.
14. Bork K,. Human pasteurized C1-inhibitor concentrate for the treatment of hereditary angioedema due to C1-inhibitor deficiency. Expert Rev Clin Immunol 2011; 7: 723-733.
15. Bork K, Korger G, Kreuz W,. Review of the long-term safety of a human pasteurized C1 inhibitor concentrate. J Allergy Clin Immunol 2012; 129: AB222. Poster presented at the 2012 AAAAI Annual Meeting, Orlando, Florida.
16. Bowen T, Cicardi M, Farkas H, etal. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
17. Berrettini M, Lämmle B, White T, etal. Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 1986; 68: 455-462.
18. Craig T, Pürsün EA, Bork K, etal. WAO Guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5: 182-199.
19. Jiang H, Zhang HM, Frank MM,. Subcutaneous infusion of human C1 inhibitor in swine. Clin Immunol 2010; 136: 323-328.
20. Schranz J, Levy R, Lumry W, etal. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) Cinryze® C1 inhibitor (C1 INH) with recombinant human hyaluronidase (rHuPH20) in subjects with hereditary angioedema (HAE). J Allergy Clin Immunol 2012; 129: AB369. Poster presented at the 2012 AAAAI Annual Meeting, Orlando, Florida.
21. ClinicalTrials.gov. A study to evaluate the safety, pharmacokinetics, and pharmacodynamics of subcutaneous CINRYZE administration. 2012 [cited 2013 May 13]. Accessed from: http://clinicaltrials.gov/ct2/show/NCT01095497
22. Zuraw BL, Sugimoto S, Curd JG,. The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. J Allergy Clin Immunol 1986; 78: 1115-1120.
23. Davis AE 3rd,. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100: S7-12.
24. Lämmle B, Zuraw BL, Heeb MJ, etal. Detection and quantitation of cleaved and uncleaved high molecular weight kininogen in plasma by ligand blotting with radiolabeled plasma prekallikrein or factor IX. Thromb Haemost 1988; 59: 151-161.
25. Nielsen EW, Johansen HT, Hogasen K, etal. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol 1996; 44: 185-192.
26. Cugno M, Cicardi M, Coppola R, etal. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 1996; 33: 361-364.
27. Bühler R, Hovinga JK, Aebi-Huber I, etal. Improved detection of proteolytically cleaved high molecular weight kininogen by immunoblotting using an antiserum against its reduced 47kDa light chain. Blood Coagul Fibrinolysis 1995; 6: 223-232.
28. McDonald TC,. Subcutaneous administration of biotherapeutics. Curr Opin Mol Ther 2010; 12: 461-470.
29. Späth PJ, Wüthrich B, Bütler R,. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema-evidence of a functionally critical level of C1-inhibitor concentration. Complement 1984; 1: 147-159.
30. Bork K, Witzke G,. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1989; 83: 677-682.
31. Farkas H, Harmat G, Füst G, etal. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol 2002; 13: 153-161.
32. Levi M, Choi G, Picavet C, etal. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117: 904-908.
33. Kaplan AP, Joseph K,. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 193-204.
34. Bernstein JA, Ritchie B, Levy RJ, etal. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Ann Allergy Asthma Immunol 2010; 105: 149-154.
35. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, etal. Pharmacokinetic analysis of human plasma-derived pasteurized factor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion 2010; 50: 354-360.
36. European Medicines Agency. Cinryze-assessment report. Procedure No. EMEA/H/C/001207. [cited 2013 Nov 13]. Available from: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Public-assessment-report/human/001207/ WC500108898.pdf
37. European Medicines Agency. Cinryze 500 Units powder and solvent for solution for injection. Summary of product characteristics. [cited 2013 Nov 13]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/001207/WC500108895.pdf
38. Brackertz D, Isler E, Kueppers F,. Half-life of C1-INH in hereditary angioneurotic oedema (HAE). Clin Allergy 1975; 1: 89-94.
39. Skoda-Smith S, Torgerson TR, Ochs HD,. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag 2010; 6: 1-10.
40. Craig TJ, Bewtra AK, Bahna SL, etal. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks-final results of the I.M.P.A.C.T.2 study. Allergy 2011; 66: 1604-1611.
41. Braun A, Kwee L, Labow MA, etal. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 1997; 14: 1472-1478.
42. Kromminga A, Schellekens H,. Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann N Y Acad Sci 2005; 1050: 257-265.
43. Schellekens H, Jiskoot W,. Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol 2006; 3: 123-130.